Proteomics Market Size & Share 2026-2035

Proteomics Market Size

The global proteomics market was valued at USD 41.2 billion in 2025. The market is expected to grow from USD 45.7 billion in 2026 to USD 126.3 billion in 2035, growing at a CAGR of 12% during the forecast period, according to the latest report published by Global Market Insights Inc.

The rising prevalence of chronic diseases and cancer is driving demand for advanced proteomics tools. For instance, the CDC reports that in the U.S., there were 1,851,238 new cancer cases in 2022. Additionally, from August 2021 to August 2023, approximately 15.8% of U.S. adults, about 38.4 million people, had diabetes. Moreover, cardiovascular diseases led to approximately 19.8 million deaths globally in 2022, accounting for 32% of all worldwide deaths. These show the critical role of proteomics in biomarker discovery, early detection, and personalized therapies for cancer, diabetes complications, and heart disease.
 

Proteomics tools encompass instruments, reagents, and services utilized in the identification, quantification, and analysis of proteins within biological systems. They include mass spectrometry platforms, protein microarrays, and label-free quantification systems, facilitating high-throughput and multiplex protein profiling. Key players accelerating growth in the proteomics market include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Bruker, and Bio-Rad. These companies drive innovation through new instrument development, forming strategic partnerships and licensing agreements, and expanding global manufacturing and distribution capabilities.
 

Between 2022 and 2024, the market grew from USD 29.9 billion to USD 37.2 billion. The growth is attributed to the rise in life science investments, growing demand for precision medicine, and the increased use of proteomics tools in drug development and diagnostics. This rapid expansion confirms the recognition of proteomics as foundational to understanding biological systems and discovering novel therapeutic targets. The development of mass spectrometers and chromatography, along with innovative approaches for data analytics are key to expanding the use of proteomics in the pharma and research. In addition, collaborative research among pharmaceutical companies, academic institutions, and biotechnology firms is accelerating this trend, transforming biomedical research globally.

Proteomics Market Trends

• Rapid innovation in the field of proteomics and the expanding role in precision medicine are some of the key factors driving the market. Companies are incorporating machine learning (ML) and artificial intelligence (AI) into proteomic workflows.
   
• For example, Thermo Fisher Scientific has cloud-based tools that use AI to optimize the discovery of biomarkers and the development of drugs in real time by analyzing complex sets of protein data. Such innovations increase the accuracy, speed, and scalability of proteomic analyses, thereby accelerating clinical adoption, boosting R&D productivity, and driving overall market growth.
   
• Moreover, the rise of single-cell proteomics represents a major breakthrough in the field. By enabling protein analysis at the individual cell level, this approach is transforming cancer research through deeper insights into tumor heterogeneity and disease progression. Additionally, in immunology, single-cell proteomics is enhancing the understanding of immune system dynamics, helping researchers design more targeted and personalized therapeutic strategies.
   
• High-throughput mass spectrometry remains the foundation of proteomics research, and technological advances in this field are expected to continue driving market growth. Modern systems are providing better sensitivity, speed and accuracy. These systems continue to improve the quality of data in large-scale protein studies. Such advances will also make proteomic techniques more suitable for use in clinical diagnostics rather than only in research-focused laboratories.
   
• Further, the adoption of cloud-based proteomics platforms is gaining momentum. These solutions allow secure storage, sharing, and analysis of vast datasets, supporting global collaboration and real-time data processing. Such capabilities are especially valuable for multi-center and large-scale clinical studies.
   
• Moreover, strategic partnerships, collaborations, and acquisitions are shaping the competitive landscape. Companies are aligning with research institutions and expanding their product portfolios to strengthen innovation pipelines and global presence.
   
• Despite challenges such as high costs, technical complexity, and data standardization issues, growing adoption in emerging markets, broader clinical use, and continuous technological advancements are expected to support sustained long-term growth of the market.
   

Proteomics Market Analysis

Based on the component, the proteomics market is segmented into instruments, consumables and reagents, and services. The consumables and reagents segment accounted for 69.4% of the market in 2025 and is expected to grow at a CAGR of 12.3% during the forecast period.
 

• The consumables and reagents segment represents a major share of the market, owing to the increasing demand for high-quality materials required for protein identification, quantification, and functional analysis.
   
• Consumables and reagents include products such as protein chips, assay kits, reagents, buffers, chromatography columns, and electrophoresis gels, which are repeatedly used for various proteomic analyses, including mass spectrometry, chromatography, and protein microarrays, resulting in recurring revenue generation.
   
• The increase in the use of quantitative proteomics in drug discovery, biomarker research, and diagnostics has greatly driven the use of reagents and consumables. This is because consumables are single-use, and to maintain accuracy and uniformity in experimental procedures, they must be purchased frequently. As a result, the consumables and reagents segment will continue to witness strong growth over the forecast years.
   
• On the other hand, the instruments segment was valued at USD 8 billion in 2025, driven by the growing adoption of advanced mass spectrometry platforms for high-resolution and high-sensitivity protein analysis. High demand for automated, high-throughput workflows in clinical research and drug discovery is enhancing the demand for next-generation instruments.
   

Based on the technique, the proteomics market is segmented into advanced techniques, conventional techniques, bioinformatics and computational analysis, and other techniques. The advanced technique segment dominated the market in 2025 with a revenue of USD 21.6 billion.
 

• The advanced technique segment is further bifurcated into mass spectrometry, gel-based technique, protein microarray, and other advanced techniques. The techniques play a central role in high-precision protein analysis across research, clinical, and pharmaceutical applications.
   
• Technologies such as mass spectrometry coupled with liquid chromatography, protein microarrays, and advanced gel-based methods offer superior sensitivity, accuracy, and throughput compared to conventional approaches.
   
• Together, these advanced techniques drive innovation in disease research, drug development, and personalized medicine. Owing to their high adoption in pharmaceutical and research applications, these advanced techniques are the primary contributors to the growth of the market.
   
• The conventional technique segment, on the other hand, held the second-highest market share due to continued reliance on established methods like Western blotting and ELISA. These techniques remain cost-effective, widely available, and essential for basic protein analysis.
   

Based on the application, the proteomics market is segmented into clinical diagnostics and clinical research. The clinical research segment dominated the market in 2025 with a market share of 53.8%. This growth can be attributed to its key role in advancing precision medicine, drug development, and disease diagnostics. On the other hand, the clinical diagnostics segment is anticipated to witness growth at a CAGR of 12.5% between 2026 – 2035. Proteomic technologies are widely used in clinical diagnoses due to their high sensitivity and specific identification of disease-related protein biomarkers.
 

• Proteomic tools are widely used in clinical research owing to the extensive use of proteomic technologies in disease mechanism studies, biomarker discovery, and translational research.
   
• Proteomics plays a critical role in identifying disease-specific proteins, thereby supporting early diagnosis, patient classification, and therapy response assessment, especially in chronic diseases such as cancers, neurology, and cardiovascular research.
   
• In addition, the growing number of clinical trials, coupled with high R&D investments from pharmaceutical companies, academic institutions, and government funding, has accelerated the adoption of advanced proteomic tools in clinical research settings.

Based on the end use, proteomics market is classified into pharmaceutical and biopharmaceutical companies, academic and research institutions, laboratories, and other end users. The pharmaceutical and biotechnology companies segment dominated the market with 50% market share in 2025.
 

• The pharmaceutical and biopharmaceutical companies segment constitutes a considerable portion of the market, driven by the need for sophisticated analytical instrumentation in drug discovery, development, and validation.
   
• Pharmaceutical and biopharmaceutical companies implement proteomic strategies to measure the efficacy of a drug and identify potential drug toxicity. Proteomics also facilitates the discovery of biomarkers critical for the development of targeted therapies and companion diagnostics within the scope of personalized medicine.
   
• In the production of biopharmaceuticals, proteomic profiling ensures the quality and uniformity of the end product by overseeing the expression, purity, and post-translational modifications of the proteins involved. The use of AI-based predictive analytics and automated systems in proteomic workflows continues to improve the pace and precision of research.
   
• Meanwhile, the academic and research institutions segment is expected to reach USD 31.5 billion by 2035, driven by increased proteomics studies in disease research and biomarker discovery. Government funding and advanced technologies further support this growth.

North America Proteomics Market

North America proteomics industry was valued at USD 19.9 billion in 2025 and is projected to reach USD 61.9 billion by 2035, growing at a CAGR of 12.2% over the forecast years.
 

• The North America market is benefiting from the region's solid background in biomedical research, rapid technological advancements, and a comprehensive healthcare system.
   
• The region's strong focus on life sciences, deployment of cutting-edge proteomics devices, and the utilization of AI for data analysis in proteomics are benefiting the North American market.
   
• Collaborative efforts among academic entities, biotech industries, and pharmaceutical companies further drive significant progress in protein profiling, biomarker development, and the customization of medicinal therapies.
   
• Moreover, market expansion is increasingly fueled by the positive government policies related to research in genomics and proteomics, which further boost the regional market growth.
   

The U.S. proteomics market was valued at USD 12.8 billion and USD 14.3 billion in 2022 and 2023, respectively. The market size reached USD 17.7 billion in 2025, growing from USD 16 billion in 2024.
 

• A strong research and academic ecosystem, a large number of biotechnological startups, and pharmaceutical companies continue to drive and develop the U.S. market.
   
• The country ranks top worldwide in technology, finance, life sciences research, and development policies.
   
• Proteomics use has increased across numerous disciplines including personalized medicine, biomarker discovery, and disease diagnosis, enabling better understanding of complex biological systems.
   
• The U.S. is at the forefront of the innovation of clinically applied proteomics. The increasing need for proteomics and precision therapeutics in the early diagnosis of diseases continues to drive the U.S. as the global leader in the innovation of clinically applied proteomics.
   

Europe Proteomics Market

The Europe proteomics industry was valued at USD 13.4 billion in 2025 and is anticipated to exhibit lucrative growth over the forecast period.
 

• The European market is witnessing sustained growth due to strong collaborations between academia and industry, supportive regulations, and increasing clinical adoption.
   
• European governments and the European Commission, through national and cross-border proteomics-focused research, biomarker development, and translational research initiatives, contribute to the advancements of precision healthcare.
   
• The aging population alongside the increased burden of chronic diseases, particularly cancer and neurological disorders, drive the clinical application of proteomics for diagnostic and therapeutic development, thus supporting regional market growth.
   

Germany dominates the European proteomics market, showcasing strong growth potential.
 

• Germany has one of the most advanced markets in Europe due to strong federal funding, innovative research infrastructure, and a thriving biotechnology industry. There are many proteomics institutes and associations, such as the Max Planck Society and Helmholtz Centers, which promote the development of protein analytics and systems biology.
   
• Integrating proteomics into the drug-discovery process, clinical trials, and personalized medicine has become common practice among German pharmaceutical and diagnostics companies. The presence of innovative and advanced instrument manufacturing companies and startups accelerates the advancement and commercialization of technology.
   
• Additionally, Germany’s focus on quality standards, automation, and data integration strengthens its position as a key European hub for translational proteomics research and industry development.
   

Asia Pacific Proteomics Market

The Asia Pacific proteomics industry is anticipated to grow at the highest CAGR of 12.5% during the analysis timeframe.
 

• Asia Pacific market is growing rapidly driven by investments in life-sciences, the biotechnology sector, government funding, and improving healthcare infrastructure.
   
• China, Japan, South Korea, and India are developing as important hubs for proteomic research and innovation. Local academic institutes and pharmaceutical companies are now adopting advanced protein analysis for drug discovery and disease diagnostics.
   
• Collaborative research programs and the rise of contract research organizations are accelerating market growth.
   
• Additionally, the region’s large patient population and focus on precision medicine create strong demand for proteomic technologies.
   

China proteomics market is estimated to grow with a significant CAGR in the Asia Pacific market.
 

• There is strong growth in proteomics in China, which is supported by government activities, rapid growth of the biotechnology sector, and new synergies between academia and industry.
   
• Growing focus on precision medicine, new therapy development for cancer, and infectious diseases has driven the adoption of new proteomic technologies. Furthermore, national initiatives support the integration of various omics data for the creation of novel, innovative, and data-driven healthcare solutions, which are raising innovation across universities and research institutes.
   
• At the same time, the domestically developed solutions in mass spectrometry and bioinformatics promote independence from external suppliers.
   
• The rise of large-scale clinical proteomics studies and investment in biobanking further enhance China’s role as a regional leader, positioning it as a key contributor to the Asia Pacific market.
   

Latin American Proteomics Market

Brazil leads the Latin American proteomics industry, exhibiting remarkable growth during the analysis period.
 

• Investments in biomedical research, academic developments, and improvements in regional healthcare are helping to expand the market in Brazil.
   
• Universities and research institutions in the country are using proteomic technologies to study infectious diseases, cancer, and metabolic diseases.
   
• Local skills are being augmented through government programs that support biotechnology and collaboration with foreign research institutes.
   
• Also, the implementation of mass spectrometry and protein microarray platforms is being motivated by the increasing need for personalized medicine and better diagnostic systems.
   
• Despite challenges such as limited funding and infrastructure gaps, Brazil is emerging as a key Latin American hub for proteomics innovation and translational research.
   

Middle East and Africa Proteomics Market

Saudi Arabia proteomics industry is expected to experience substantial growth in the Middle East and Africa market in 2025.
 

• Saudi Arabia’s proteomics industry is gaining traction as the country invests in biotechnology and healthcare innovations as part of the Vision 2030 program.
   
• National initiatives in genomics and life sciences are expanding to proteomics research focusing on precision medicine and disease biomarker discovery.
   
• Top-tier universities and medical schools are opening new clinical biochemistry research labs with mass spectrometers and bioinformatics tools.
   
• In addition, partnerships with international biotech companies and regional research networks are fostering technology transfer and skill development, thereby boosting market growth.
   

Proteomics Market Share

The proteomics industry presents a dynamic and moderately consolidated competitive landscape, shaped by the presence of leading analytical instrument manufacturers, biotechnology firms, and proteomics service providers. Top 5 companies, including Thermo Fisher Scientific (Olink), SomaLogic Operating, Biognosys, Agilent Technologies, and Bruker, collectively account for approximately 54.5% of the global market share. Their dominance is fueled by continuous advancements in mass spectrometry, antibody-based proteomics, and data-driven biomarker discovery platforms. These companies are increasingly investing in technologies that enable ultra-sensitive protein quantification, multi-omics integration, and high-throughput clinical proteomics applications. The market’s evolution is further supported by growing adoption of proteomic profiling in oncology, neurodegenerative diseases, and drug development.
 

Emerging players such as Seer, Inc. and Quantum-Si, Inc. are driving innovation through next-generation nanoparticle and single-molecule detection platforms, particularly targeting growth opportunities in Asia-Pacific and Europe.
 

Amid accelerating regulatory clarity, advancements in automation, and expanding government-backed precision health initiatives, the proteomics market is rapidly maturing. Companies are broadening their product ecosystems to support translational research, real-time diagnostics, and personalized therapeutics, ensuring sustained innovation, deeper insights, and long-term global market expansion.
 

Proteomics Market Companies

Prominent players operating in the proteomics industry are as mentioned below:

• Agilent Technologies
• Biognosys
• Bio-Rad
• Bruker
• Creative Proteomics
• F. Hoffmann-La Roche
• Merck KGaA
• PREOMICS
• Promega
• Quantum-Si
• Seer
• SomaLogic Operating
• Thermo Fisher Scientific (Olink)
• Waters
   

Thermo Fisher Scientific (Olink)

Thermo Fisher’s USP lies in its comprehensive proteomics ecosystem, combining Olink’s proximity extension assays, advanced Orbitrap mass spectrometers, and scalable informatics platforms. This enables ultra-sensitive protein quantification and biomarker discovery. For instance, Thermo’s Orbitrap Astral system offers unmatched resolution for translational research and clinical proteomics applications worldwide.
 

SomaLogic Operating

SomaLogic differentiates itself through its SomaScan platform, capable of simultaneously quantifying over 11,000 proteins from a small plasma sample. Its aptamer-based technology provides unmatched scalability for population-level studies. For example, SomaLogic partners with Novo Nordisk to accelerate precision medicine through large-scale proteomic biomarker identification.
 

Biognosys

Biognosys stands out for its expertise in mass spectrometry-based proteomics and data-independent acquisition (DIA) technologies. Its Spectronaut software delivers advanced data analysis and reproducibility across discovery and targeted proteomics. A notable example is its collaboration with Bayer to identify novel drug targets using high-resolution proteomic profiling.
 

Proteomics Industry News

• In February 2025, Thermo Fisher Scientific (Olink) launched the Orbitrap Ascend Ultra platform, delivering enhanced mass accuracy and throughput for large-scale proteomic studies. The system integrates seamlessly with Olink’s PEA technology, enabling researchers to profile thousands of proteins with improved sensitivity for translational and clinical biomarker discovery.
   
• In February 2025, Thermo Fisher Scientific (Olink) was selected by the UK Biobank Pharma Proteomics Project to analyze over 5,400 proteins across 600,000 samples, marking the world’s largest human proteome study. This milestone has further strengthened the company’s leadership position in the market.
   
• In July 2024, Thermo Fisher Scientific completed the acquisition of Olink Holding AB, significantly expanding its presence in the proteomics market. The acquisition strengthened Thermo’s position in precision research and clinical biomarker discovery by integrating Olink’s advanced proximity extension assay (PEA) technology with Thermo’s mass spectrometry portfolio.
   
• In May 2024, Biognosys introduced Spectronaut 19, featuring next-generation algorithms for faster and more accurate DIA-MS data processing. The new release features next-generation AI-powered algorithms to deliver faster, more accurate data processing, strengthening the company’s position in precision proteomics.
   

The proteomics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Instruments
• Consumables and reagents
• Services

Market, By Technique

• Advanced technique
• Conventional technique
• Bioinformatics and computational analysis
• Other techniques

Market, By Application

• Clinical diagnostics
• Clinical research

Market, By End Use

• Pharmaceutical and biopharmaceutical companies
• Academic and research institutions
• Laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE